Thalidomide-O-amido-PEG4-C2-NH2
Code | Size | Price |
---|
TAR-T39380-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T39380-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Thalidomide-O-amido-PEG4-C2-NH2 is a synthesized conjugate compound that combines a Thalidomide-based cereblon ligand with a linker commonly used in PROTAC technology. It acts as an E3 ligase ligand-linker conjugate, enabling targeted protein degradation.
CAS:
1957236-22-4
Molecular Weight:
550.565
Purity:
0.98
SMILES:
NCCOCCOCCOCCOCCNC(=O)COc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12
References
Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.
James Bradner, et al. Methods to induce targeted protein degradation through bifunctional molecules. WO2016105518A1.
Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.?Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11.